Bank of America
KLDO

Bank of America’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Bank of America’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-16,228
Closed -$27K – 8807
2022
Q1 		$27K Sell
16,228
-7,085
-30% -$12.6K ﹤0.01% 7413
2021
Q4 		$56K Sell
23,313
-3,574
-13% -$14.6K ﹤0.01% 7166
2021
Q3 		$147K Buy
26,887
+12,132
+82% +$75.3K ﹤0.01% 6506
2021
Q2 		$110K Buy
14,755
+3,364
+30% +$23.8K ﹤0.01% 6471
2021
Q1 		$92K Buy
11,391
+7,693
+208% +$83.8K ﹤0.01% 6424
2020
Q4 		$34K Sell
3,698
-1,084
-23% -$8.89K ﹤0.01% 6460
2020
Q3 		$53K Sell
4,782
-4,151
-46% -$28.8K ﹤0.01% 5991
2020
Q2 		$67K Buy
8,933
+5,540
+163% +$37.1K ﹤0.01% 5854
2020
Q1 		$21K Sell
3,393
-57,840
-94% -$377K ﹤0.01% 6168
2019
Q4 		$307K Buy
61,233
+58,412
+2,071% +$371K ﹤0.01% 5348
2019
Q3 		$22K Buy
2,821
+1,786
+173% +$15.5K ﹤0.01% 6571
2019
Q2 		$11K Sell
1,035
-1,318
-56% -$19.2K ﹤0.01% 6718
2019
Q1 		$34K Buy
+2,353
New +$32.4K ﹤0.01% 6343

Other funds holding KLDO

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Bank of America's KLDO Position: Q2 2022 in Review

Bank of America sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 16,228 shares — an estimated $27K sold.

Bank of America first reported a position in KLDO in Q1 2019 and held it in 13 quarters. The position peaked at $307K in Q4 2019. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

  • Bank of America reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Bank of America sold 16,228 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $27K.
  • Bank of America first reported a position in Kaleido Biosciences, Inc. Common Stock in Q1 2019 and held it in 13 quarters.
  • Bank of America's Kaleido Biosciences, Inc. Common Stock position peaked at $307K in Q4 2019.
  • 3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on Bank of America's 13F filing for Q2 2022, filed 12 Aug 2022.